Anthropic in October last year iterated its Claude AI model to better cater to biopharma purposes. Sanofi, Novo Nordisk, AbbVie and others already use Claude in their operations.
AI Giant Anthropic Leans Into Life Sciences With $400M Coefficient Bio Catch Read More »
Some disease areas bucked the trend of shrinking pipelines, however, with immune and cardiovascular indications seeing an upward trend in investigational assets.
Pharma Pipeline Stalls for First Time in Decades: Citeline Read More »
While an acquisition is a good exit for Soleno Therapeutics, the company’s acceptance of Neurocrine Biosciences’ $53-per-share offer came as a surprise to Stifel analysts given the potential growth of Vykat XR, approved last year for extreme hunger in patients with Prader-Willi syndrome.
Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal Read More »
Takeda and Denali Therapeutics first partnered in early 2018 to advance drugs for neurodegenerative diseases. One asset, for Alzheimer’s disease, was previously discontinued after an FDA hold and disappointing early data.
Takeda Breaks Up With Denali, Dumps Dementia Drug Read More »
From patient intake to final reimbursement, data quality is indispensable.
Explore how centralizing dental credentialing and directories reduces fragmentation, risk and costs.
Looking beyond fragmentation: How centralization can fix dental provider data Read More »
Healthcare doesn’t have an AI experimentation problem. It has an execution gap — and that gap is widening.
While recent FDA guidance speaks to the agency’s support of innovative trial designs—including the use of external controls—the application of this flexibility appears to be inconsistent. One former regulator says the situation is more nuanced.
FDA Reversals in Rare Disease Space Highlight Confusion Around External Controls Read More »
The upcoming FDA decision for Replimune’s advanced melanoma drug could be a litmus test for the agency’s future regulatory decision-making, analysts say, with implications stretching well beyond one company.
Biotech Looks to Replimune RP1 Decision as ‘First Indicator’ of FDA Direction Read More »
Nobel laureate Sir Michael Houghton and colleagues at Applied Pharmaceutical Innovation (API) outline how rigorous early testing, smart IP and regulatory planning, and scalable CMC choices can help founders reach first-in-human faster.
Lean Derisking: Smart Ways to Cross Drug Development’s “Valley of Death” Read More »
